.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 5,453,510

« Back to Dashboard

Claims for Patent: 5,453,510

Title: Neuromuscular blocking agents
Abstract:1R-cis,1'R-cis isomer of a 2',2'-(3,11-dioxo-4,10-dioxatridecylene)-bis(1,2,3,4-tetrahydro-6, 7-dimethoxy-2-methyl-1-veratrylisoquinolium) said, substantially free from other geometrical and optical isomers thereof. The 1R-cis,1'R-cis isomer has been found to have an advantageous combination of pharmacological properties, notably greater neuromuscular blocking potency, weaker histamine-releasing potency, and at equivalent levels of neuromuscular blockade, fewer potential adverse effects on the autonomic nervous system (sympathetic and parasympathetic blockage), in comparison with the known mixture of geometrical and optical isomers.
Inventor(s): Hill; Derek A. (Dartford, GB2), Turner; Geoffrey L. (Dartford, GB2)
Assignee: Burroughs Wellcome Co. (Research Triangle Park, NC)
Application Number:07/911,887
Patent Claims: 1. A physiologically acceptable 1R-cis,1'R-cis-2,2'-(3,11-dioxo-4,10-dioxatridecamethylene)-bis-(1,2,3,4-t etrahydro-6,7-dimethoxy-2-methyl-1-veratrylisoquinolinium salt being substantially free of other geometric or optical isomers thereof, the amount of said other geometric or optical isomers thereof being less than 8% w/w based on the combined weight of said physiologically acceptable salt and any of said geometric or optical isomers.

2. The salt of claim 1 in which said other geometric or optical isomers thereof is less than 5% w/w.

3. The salt of claim 1 in which said other geometric or optical isomers thereof is less than 2% w/w.

4. A physiologically acceptable 1R-cis,1'R-cis-2,2'-(3,11-dioxo-4,10-dioxatridecamethylene)-1,2,3,4-tetrah ydro-6,7-dimethoxy-2-methyl-1-veratrylisoquinolinium besylate salt being substantially free of other geometric or optical isomers being less than 8% w/w based on the combined weight of said besylate salt and any of said geometric or optical isomers thereof.

5. The salt of claim 1 in which said other geometric or optical isomers thereof is less than 5% w/w.

6. The salt of claim 1 in which said other geometric or optical isomers thereof is less than 2% w/w.

7. A physiologically acceptable 1R-cis,1'-R-cis-2,2'-(3,11-dioxo-4,10-dioxatridecamethylene)-bis-(1,2,3,4- tetrahydro-6,7-dimethoxy-2-methyl-1-veratrylisoquinolinium mesylate salt being substantially free of other geometric or optical isomers thereof the amount of, said other geometric or optical isomers being less than 8% w/w based on the combined weight of said mesylate salt and any of said geometric or optical isomers thereof.

8. The salt of claim 7 in which said other geometric or optical isomers thereof is less than 5% w/w.

9. The salt of claim 7 in which said other geometric or optical isomers thereof is less than 2% w/w.

10. A pharmaceutically composition comprising the physiologically acceptable salt of claim 1, 2 or 3 in combination with a pharmaceutically acceptable therefor.

11. A pharmaceutically composition comprising the besylate salt of claim 4, 5 or 6 in combination with a pharmaceutical acceptable carrier therefor.

12. A pharmaceutical composition comprising the mesylate salt of claim 7, 8 or 9 in combination with a pharmaceutically acceptable carrier therefor.

13. A method of producing neuromuscular blockage in an animal which comprises administering by injection or infusion to said animal an effective neuromuscular blockade amount of a pharmacologically acceptable liquid containing a physiologically acceptable 1R-cis,1'R-cis-2,2'-(3,11-dioxo-4,10-dioxatridecamethylene)-bis-(1,2,3,4-t etrahydro-6,7-dimethoxy-2-methyl-1-veratrylisoquinolinium salt being substantially free of other geometric or optical isomers thereof, the amount of said other geometric or optical isomers thereof being less than 8% w/w based on the combined weight of said physiologically acceptable salt and any of said geometric or optical isomers.

14. The method of claim 11 in which said other geometric or optical isomers thereof is less than 5% w/w.

15. The method of claim 11 in which said other geometric or optical isomers thereof is less than 2% w/w.

16. The method of claim 13, 14 or 15 in which the pharmacologically acceptable salt is the mesylate salt.

17. The method of claim 13 in which the pharmacologically acceptable salt is the besylate salt.

18. The method of claim 14 in which pharmacologically acceptable salt is the besylate salt.

19. The method of claim 15 in which the pharmacologically acceptable salt is the besylate salt.

20. The method of claim 13, 14, 15, 16, 17, 18 or 19 in which the animal is a human.

21. The salt of claim 1, 2, 3, 4, 5, 6, 7, 8 or 9 in solid form.

22. The method of claim 17 in which the animal is a human.

23. The method of claim 18 in which the animal is a human.

24. The method of claim 19 in which the animal is a human.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc